STEPHEN J POWERS
Broker in Waltham, MA
License number
Massachusetts 9004904
Issued Date
Oct 13, 1993
Expiration Date
Sep 7, 1996
Type
Salesperson
Address
Address
Waltham, MA 02454
Professional information
T Cell Peptides Of The Crx Jii Allergen
US Patent:
6090386, Jul 18, 2000
Filed:
Jun 6, 1995
Appl. No.:
8/467023
Inventors:
Irwin J. Griffith - North Reading MA
Joanne Pollock - Arlington MA
Julian F. Bond - Weymouth MA
Richard D. Garman - Arlington MA
Mei-chang Kuo - Winchester MA
Stephen P. Powers - Waltham MA
Mark A. Exley - Brookline MA
Xian Chen - North Chelmsford MA
Ze'ev Shaked - Berkeley CA
Joanne Pollock - Arlington MA
Julian F. Bond - Weymouth MA
Richard D. Garman - Arlington MA
Mei-chang Kuo - Winchester MA
Stephen P. Powers - Waltham MA
Mark A. Exley - Brookline MA
Xian Chen - North Chelmsford MA
Ze'ev Shaked - Berkeley CA
International Classification:
A61K 3810, A61K 3936, C07K 708, C07K 14415
US Classification:
4241851
Abstract:
The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
2003006, Apr 10, 2003
Filed:
Apr 1, 2002
Appl. No.:
10/115580
Inventors:
Philip Swain - Boston MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
Assignee:
Xenova Research Limited
International Classification:
G01N033/53, C07K014/435, G01N033/543
US Classification:
530/404000, 530/405000, 530/406000, 435/007100, 436/518000
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
5773003, Jun 30, 1998
Filed:
Jun 1, 1995
Appl. No.:
8/456444
Inventors:
Philip A. Swain - Brighton MA
Victoria Carol Schad - Cambridge MA
Julia Lea Greenstein - West Newton MA
Mark Adrian Exley - Chestnut Hill MA
Barbara Saxton Fox - Wayland MA
Stephen P. Powers - Waltham MA
Malcolm L. Gefter - Lincoln MA
Victoria Carol Schad - Cambridge MA
Julia Lea Greenstein - West Newton MA
Mark Adrian Exley - Chestnut Hill MA
Barbara Saxton Fox - Wayland MA
Stephen P. Powers - Waltham MA
Malcolm L. Gefter - Lincoln MA
Assignee:
ImmuLogic, Inc. - Waltham MA
International Classification:
A61K 39385, A61K 3912
US Classification:
4241931
Abstract:
Hapten-carrier conjugates capable of eliciting anti hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Anti-hapten antibodies elicited compete with free hapten upon subsequent challenge of a vaccinated individual. Methods of preparing the conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
2006028, Dec 21, 2006
Filed:
Jun 19, 2006
Appl. No.:
11/472222
Inventors:
Philip Swain - Boston MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
International Classification:
C07K 16/18, C07K 14/47, C07D 451/02, A61K 39/395, A61K 39/00
US Classification:
424133100, 424184100, 530388100, 530409000, 546132000
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
2006005, Mar 16, 2006
Filed:
Feb 23, 2005
Appl. No.:
11/066718
Inventors:
Philip Swain - Boston MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
International Classification:
A61K 39/00
US Classification:
514002000, 530300000
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are, disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
2005012, Jun 9, 2005
Filed:
Aug 22, 2003
Appl. No.:
10/647071
Inventors:
Philip Swain - Boston MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
International Classification:
C12P021/04, C07K014/47, C12N005/06
US Classification:
435326000, 530403000, 435070210
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
2006028, Dec 21, 2006
Filed:
Jun 19, 2006
Appl. No.:
11/472221
Inventors:
Philiip Swain - Boston MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Stephen Powers - Waltham MA, US
Malcolm Gefter - Lincoln MA, US
International Classification:
A61K 39/395, A61K 39/00, C07D 451/02, C07K 16/18, C07K 14/47
US Classification:
424133100, 424184100, 546132000, 530388100, 530409000
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
6054127, Apr 25, 2000
Filed:
Jun 27, 1997
Appl. No.:
8/884497
Inventors:
Philip A. Swain - Boston MA
Victoria C. Schad - Cambridge MA
Julia L. Greenstein - West Newton MA
Mark A. Exley - Chestnut Hill MA
Barbara S. Fox - Wayland MA
Stephen P. Powers - Waltham MA
Malcolm L. Gefter - Lincoln MA
Thomas J. Briner - Arlington MA
Victoria C. Schad - Cambridge MA
Julia L. Greenstein - West Newton MA
Mark A. Exley - Chestnut Hill MA
Barbara S. Fox - Wayland MA
Stephen P. Powers - Waltham MA
Malcolm L. Gefter - Lincoln MA
Thomas J. Briner - Arlington MA
Assignee:
Immulogic Pharmaceutical Corporation - Waltham MA
International Classification:
A61K 39385, C07D45102
US Classification:
4241941
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
2006028, Dec 21, 2006
Filed:
Jun 19, 2006
Appl. No.:
11/472220
Inventors:
Philip Swain - Boston MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Malcolm Gefter - Lincoln MA, US
Stephen Powers - Waltham MA, US
Victoria Schad - Cambridge MA, US
Julia Greenstein - West Newton MA, US
Mark Exley - Chestnut Hill MA, US
Barbara Fox - Wayland MA, US
Malcolm Gefter - Lincoln MA, US
Stephen Powers - Waltham MA, US
International Classification:
C07K 14/47, C07D 451/02, C07K 16/18, A61K 39/395, A61K 39/00
US Classification:
424133100, 424184100, 546132000, 530388100, 530409000
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Hapten-Carrier Conjugates For Use In Drug-Abuse Therapy And Methods For Preparation Of Same
US Patent:
5876727, Mar 2, 1999
Filed:
Sep 30, 1996
Appl. No.:
8/720487
Inventors:
Philip A. Swain - Boston MA
Victoria C. Schad - Cambridge MA
Julia L. Greenstein - West Newton MA
Mark A. Exley - Chestnut Hill MA
Barbara S. Fox - Wayland MA
Stephen P. Powers - Waltham MA
Malcolm L. Gefter - Lincoln MA
Victoria C. Schad - Cambridge MA
Julia L. Greenstein - West Newton MA
Mark A. Exley - Chestnut Hill MA
Barbara S. Fox - Wayland MA
Stephen P. Powers - Waltham MA
Malcolm L. Gefter - Lincoln MA
Assignee:
ImmuLogic Pharmaceutical Corporation - Waltham MA
International Classification:
A61K 39385, A61K 39395, C07D45102
US Classification:
4241931
Abstract:
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.